We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

83 hedge funds and large institutions have $175M invested in Adamas Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

62% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less funds holding

Funds holding: 89 → 83 (-6)

30% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 20

35% less capital invested

Capital invested by funds: $268M → $175M (-$93.1M)

Holders
83
Holders Change
-6
Holders Change %
-6.74%
% of All Funds
2.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
14
Increased
34
Reduced
21
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$7.68M
2
SCM
Sio Capital Management
New York
+$2.32M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.98M
4
SM
Sabby Management
Florida
+$1.75M
5
Invesco
Invesco
Georgia
+$1.66M

Top Sellers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
-$9.44M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$4.86M
3
CPH
C Partners Holding
Switzerland
-$3.69M
4
Fidelity International
Fidelity International
Bermuda
-$1.42M
5
EI
EAM Investors
California
-$1.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
SGAM
26
Smith Group Asset Management
Texas
$1.1M -$228 -10 -0%
JP Morgan Chase
27
JP Morgan Chase
New York
$1.03M +$30.5K +1,339 +2%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$937K +$24.4K +1,071 +2%
SIM
29
Spark Investment Management
New York
$935K -$77.4K -3,400 -6%
GPCM
30
Granite Point Capital Management
Massachusetts
$931K -$141K -6,182 -10%
Millennium Management
31
Millennium Management
New York
$896K +$816K +35,883 +203%
Geode Capital Management
32
Geode Capital Management
Massachusetts
$861K +$53.8K +2,363 +5%
ZIM
33
Zacks Investment Management
Illinois
$759K +$121K +5,302 +13%
BA
34
BlackRock Advisors
Delaware
$752K -$104K -4,570 -9%
PAM
35
Private Asset Management
California
$686K -$152K -6,690 -14%
BIM
36
BlackRock Investment Management
Delaware
$678K +$30.6K +1,346 +3%
RFC
37
Russell Frank Company
Washington
$638K -$1.2M -52,821 -58%
American Century Companies
38
American Century Companies
Missouri
$593K +$806K +35,449 New
TCIM
39
TIAA CREF Investment Management
New York
$581K +$287K +12,633 +57%
GCP
40
GSA Capital Partners
United Kingdom
$542K +$737K +32,403 New
JAM
41
JW Asset Management
Florida
$505K +$686K +30,140 New
BOS
42
Bingham Osborn & Scarborough
California
$502K – – –
CCMU
43
Cheyne Capital Management (UK)
United Kingdom
$502K +$683K +30,000 New
SO
44
STRS Ohio
Ohio
$453K – – –
TAM
45
Tocqueville Asset Management
New York
$419K – – –
NCCM
46
Nine Chapters Capital Management
New Jersey
$385K +$523K +23,000 New
UBS AM
47
UBS AM
Illinois
$349K -$34.9K -1,533 -7%
Asset Management One
48
Asset Management One
Japan
$319K – – –
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$316K -$2.27K -100 -0.5%
D.E. Shaw & Co
50
D.E. Shaw & Co
New York
$300K +$408K +17,936 New
1
2
3 4 5

ADMS Hedge Fund Activity: Q3 2015 in Review

83 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2015, worth a combined $175M — down 35% from $268M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ADMS and 14 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 34 added.

The largest buyer was Great Point Partners, adding an estimated $7.68M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $9.44M sold.

  • 83 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2015, down from 89 in Q2 2015.
  • Funds reported $175M of Adamas Pharmaceuticals stock for Q3 2015, down 35% quarter-over-quarter.
  • 14 funds opened new Adamas Pharmaceuticals positions in Q3 2015 and 20 closed out, a net change of -6 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2015 was Great Point Partners, an estimated $7.68M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2015 was EverPoint Asset Management, an estimated $9.44M sold.

Based on aggregated 13F filings for Q3 2015.